Welcome!

News Feed Item

Orca Pharmaceuticals Achieves Development Milestone and Secures Additional Funding

OXFORD, England, April 28, 2014 /PRNewswire-USNewswire/ -- Orca Pharmaceuticals, a biotechnology start-up developing RORgamma inhibitors for the treatment of autoimmune diseases, has announced a further investment of $1.3 million from BioMotiv, a drug development accelerator based in Cleveland, Ohio and affiliated with The Harrington Project.  Founded in 2013, the company's technology is based on intellectual property developed in the laboratory of Professor Dan Littman of New York University, a world leader in Th17 cell immunology.  Orca also has close ties with Oxford University immunologists who are playing a key role in identifying promising therapeutic indications and selecting an optimised development candidate.

Orca Pharmaceuticals logo

"This additional funding endorses the strength of the Orca program and provides resources for the advancement of a development candidate," said Roy Pettipher, PhD, founder and Chief Scientific Officer of Orca Pharmaceuticals.

Orca Pharmaceuticals is developing an oral drug to treat a range of autoimmune diseases, with psoriasis as the primary therapeutic target. Working with Evotec AG, the company has developed a series of potent and selective compounds with pharmaceutical properties that are amenable to clinical development. The additional investment will enable the company to select a clinical candidate optimised for activity on key pathogenic immune cells.

"The powerful combination of high quality medicinal chemistry, target structure analysis, and leading edge biological screening has enabled Orca to obtain potentially best-in-class RORgamma inhibitors targeting a variety of immune diseases," said David C. U'Prichard, PhD, Board Chairman of Orca Pharmaceuticals, and Chief Scientific Officer of BioMotiv.

Mick Hunter, PhD, CEO of Orca Pharmaceuticals, indicated that the company is now exploring additional development partnerships with pharmaceutical companies.

Contact
Orca Pharmaceuticals Ltd
Roy Pettipher
+44 (0) 1235 841542
[email protected]

About Orca Pharmaceuticals

Orca Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization via partnership of targeted small molecule RORgamma inhibitor drugs to treat patients with autoimmune disease.  For more information, please visit: http://www.orcapharmaceuticals.com

About BioMotiv

BioMotiv is the mission-driven accelerator associated with The Harrington Project for Discovery & Development, a $250 million national initiative for advancing medicine centered at University Hospitals of Cleveland.  The focus is to accelerate breakthrough discoveries from research institutions into therapeutics for patients through an innovative model that efficiently aligns capital and collaborations.  The company leverages an experienced team and advisory board to select, fund, and actively manage and advance a portfolio of programs.  Products are advanced to clinical proof-of-concept and then partnered.   BioMotiv is interested in early-stage therapeutics in all disease areas.  Learn more at www.biomotiv.com.

Logo - http://photos.prnewswire.com/prnh/20130805/DC57374LOGO

SOURCE Orca Pharmaceuticals

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Two weeks ago (November 3-5), I attended the Cloud Expo Silicon Valley as a speaker, where I presented on the security and privacy due diligence requirements for cloud solutions. Cloud security is a topical issue for every CIO, CISO, and technology buyer. Decision-makers are always looking for insights on how to mitigate the security risks of implementing and using cloud solutions. Based on the presentation topics covered at the conference, as well as the general discussions heard between sessio...
IoT is rapidly becoming mainstream as more and more investments are made into the platforms and technology. As this movement continues to expand and gain momentum it creates a massive wall of noise that can be difficult to sift through. Unfortunately, this inevitably makes IoT less approachable for people to get started with and can hamper efforts to integrate this key technology into your own portfolio. There are so many connected products already in place today with many hundreds more on the h...
Andi Mann, Chief Technology Advocate at Splunk, is an accomplished digital business executive with extensive global expertise as a strategist, technologist, innovator, marketer, and communicator. For over 30 years across five continents, he has built success with Fortune 500 corporations, vendors, governments, and as a leading research analyst and consultant.
No hype cycles or predictions of zillions of things here. IoT is big. You get it. You know your business and have great ideas for a business transformation strategy. What comes next? Time to make it happen. In his session at @ThingsExpo, Jay Mason, Associate Partner at M&S Consulting, presented a step-by-step plan to develop your technology implementation strategy. He discussed the evaluation of communication standards and IoT messaging protocols, data analytics considerations, edge-to-cloud tec...
Today we can collect lots and lots of performance data. We build beautiful dashboards and even have fancy query languages to access and transform the data. Still performance data is a secret language only a couple of people understand. The more business becomes digital the more stakeholders are interested in this data including how it relates to business. Some of these people have never used a monitoring tool before. They have a question on their mind like “How is my application doing” but no id...
Announcing Poland #DigitalTransformation Pavilion
Digital Transformation is much more than a buzzword. The radical shift to digital mechanisms for almost every process is evident across all industries and verticals. This is often especially true in financial services, where the legacy environment is many times unable to keep up with the rapidly shifting demands of the consumer. The constant pressure to provide complete, omnichannel delivery of customer-facing solutions to meet both regulatory and customer demands is putting enormous pressure on...
In his Opening Keynote at 21st Cloud Expo, John Considine, General Manager of IBM Cloud Infrastructure, led attendees through the exciting evolution of the cloud. He looked at this major disruption from the perspective of technology, business models, and what this means for enterprises of all sizes. John Considine is General Manager of Cloud Infrastructure Services at IBM. In that role he is responsible for leading IBM’s public cloud infrastructure including strategy, development, and offering m...
CloudEXPO | DXWorldEXPO are the world's most influential, independent events where Cloud Computing was coined and where technology buyers and vendors meet to experience and discuss the big picture of Digital Transformation and all of the strategies, tactics, and tools they need to realize their goals. Sponsors of DXWorldEXPO | CloudEXPO benefit from unmatched branding, profile building and lead generation opportunities.
DXWorldEXPO LLC announced today that All in Mobile, a mobile app development company from Poland, will exhibit at the 22nd International CloudEXPO | DXWorldEXPO. All In Mobile is a mobile app development company from Poland. Since 2014, they maintain passion for developing mobile applications for enterprises and startups worldwide.
For far too long technology teams have lived in siloes. Not only physical siloes, but cultural siloes pushed by competing objectives. This includes informational siloes where business users require one set of data and tech teams require different data. DevOps intends to bridge these gaps to make tech driven operations more aligned and efficient.
The best way to leverage your CloudEXPO | DXWorldEXPO presence as a sponsor and exhibitor is to plan your news announcements around our events. The press covering CloudEXPO | DXWorldEXPO will have access to these releases and will amplify your news announcements. More than two dozen Cloud companies either set deals at our shows or have announced their mergers and acquisitions at CloudEXPO. Product announcements during our show provide your company with the most reach through our targeted audienc...
Everything run by electricity will eventually be connected to the Internet. Get ahead of the Internet of Things revolution. In his session at @ThingsExpo, Akvelon expert and IoT industry leader Sergey Grebnov provided an educational dive into the world of managing your home, workplace and all the devices they contain with the power of machine-based AI and intelligent Bot services for a completely streamlined experience.
@DevOpsSummit at Cloud Expo, taking place November 12-13 in New York City, NY, is co-located with 22nd international CloudEXPO | first international DXWorldEXPO and will feature technical sessions from a rock star conference faculty and the leading industry players in the world.
DXWorldEXPO | CloudEXPO are the world's most influential, independent events where Cloud Computing was coined and where technology buyers and vendors meet to experience and discuss the big picture of Digital Transformation and all of the strategies, tactics, and tools they need to realize their goals. Sponsors of DXWorldEXPO | CloudEXPO benefit from unmatched branding, profile building and lead generation opportunities.